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SUMMARY 
Pentazocine is usually not recognised as a dependence producing drug, in spite of accumulation of a 
number of case reports on Pentazocine abuse and dependence in the world literature. The present paper briefly re-
views earlier reports in this area and describes eighteen cases with parenteral Pentazocine abuse seen in a general ho-
spital of Delhi over a short period of time. These cases form a spectrum from isolated abuse in patients with chronic-
pain to Pentazocine being just another drug in the setting of multiple addictions. Recommendation is made for 
more judicious use of Pentazocine in view of its high dependence potential. 
History of Medicine is replete with 
examples of substances which were in-
troduced as harmless drugs, but later 
proved to have considerable abuse and de-
pendence potential. Heroin and Pethidine 
are two well known drugs of this type. 
With the introduction of a large number of 
synthetic and semisynthetic opiate congen-
ers the chances of such pharmaceutical mis-
adventures have increased substantially. 
Fuller realization of the abuse potential of a 
drug frequently comes after it has been 
used for a number of years or even decades. 
Therefore, a constant monitoring for this 
unwanted and dangerous effect is needed, 
for all suspect drugs (W.H.O., 1975). 
A considerable number of reports have 
accumulated over the years on the abuse of 
Pentazocine, which is being used very wi-
dely in the medical and surgical practice in 
the last decade. The present paper briefly 
reviews the literature in this area and re-
ports a series of eighteen cases of Pentazoc-
ine abuse seen in a general hospital of New 
Delhi. 
Review 
Pentazocine has been in clinical use for 
about fifteen years. The first case report of 
Pentazocine abuse appeared within one 
year of clinical use (Keup, 1968). After this 
a steady stream of reports have been pub-
lished in the international literature 1970; 
Alarcon et al, 1971; Levy et al, 1972 ; 1973 ; 
Halliday, 1973 ; Kirts, 1973 ; Parwatikar et 
al, 1973 ; Swanson et al, 1973 ; 1975 ; Wald-
mann and Horsfall, 1977; King and Betts, 
1978). Most of these communications are 
case reports of one to four patients ; howev-
er, a few series are larger and describe pa-
tients collected over a number of years. Re-
ports published until the mid-seventies 
were mostly of cases which were either 
clearly iatrogenic or the patient was himself 
a medical professional. However, begin-
ning 1978, street abuse of Pentazocine 
has been described (Polkis, 1978 ; Showai-
ter and Moore, 1978; Bailey, 1979; Lah-
meyer and Steingold, 1980) generally in 
combination with other drugs like Tripe-
lennamine. 
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Psychological craving and strong drug-
seeking behaviour has been demonstrated 
by almost all the reports; however, pres-
ence of tolerance and physical withdrawal 
symptoms is controversial. Swanson et al, 
1973; Waldmann and Horsfall, 1977; King 
and Betts, 1978 ; Council on Drugs, AMA, 
1969). Withdrawal symptoms described, 
are similar to, but milder than those seen 
with Morphine or Heroin. 
A number of serious complications of 
prolonged Pentazocine administration 
have been reported. Severe induration and 
sclerosis of skin and subcutaneous tissues 
with granulomatous inflammation has been 
described, associated with repeated injec-
tions (Palestine et al, 1980). Intravenous ad-
ministration of crushed tablets can result in 
pulmonary granulomas, embolism and pul-
monary edema (Ali and Bauks, 1973 ; Butch 
et al, 1979; Houck et al, 1980). Other 
complications of Pentazocine misuse are 
summarized by Lahmeyar and Steingold 
(1980). 
Case Material 
All the eighteen patients were seen 
within a period of two years in the All-India 
Institute of Medical Sciences Hospital, 
New Delhi. Out of them 16 (88.8%) were 
males and 2(11.1%) females. A majority of 
12 (66.6%) were between 21 and 40 years 
of age and 15 (83.3%) were married. The 
distribution for occupation showed some 
interesting observations. Eight (44.4%) 
were doctors, 2 (11.1 %) pharmacists and 1 
(5.5%) was a medical student. Five were 
employed in other non-medical professions 
and 2 (11.1%) were unemployed. 
The total duration of Pentazocine abuse 
was less than one year for 7 (38.8 %), one to 
two years for 6 (33.3 %), two to three years 
for 4 (22.2 %) and more than three years for 
1 (5.5 %) patient. Quantities consumed ev-
ery day varied from 30 to 90 mg for 2 pa-
tients, 90 to 180 mg for 3 patients, 180 to 
360 mg for 10 patients and more than 
360 mg for 3 patients. 
Table 1 gives the number of patients 
who were abusing other drugs or alcohol 
on a regular basis apart from Pentazocine ; 
the total number in this table being more 
than 18 as some patients were abusing 
many drugs simultaneously. All the patients 
were administering Pentazocine parente-
rally, usually by intravenous route. 
Table 1 
Misuse of Other Drugs 
Morphine 1 
Pethidine 6 
Sedatives 6 
Cannabis 1 
Alcohol 4 
No other drug 6 
A number of patients had pre-existing 
illness, physical or psychiatric and these are 
summarized in Table 2. 
Table 2 
Pre-Existing Illness 
Physical 
Inguinal hernia 
Chronic backache 
Hiatus hernia 
Chronic pancreatitis 
Post-laparotomy adhesions 
Renal colic 
Gastric ulcer 
Chronic tongue ulcer 
Henoch-Schonelein purpura 
Angina Pectoris 
No physical illness 
Psychiatric 
Affective disorder-Bipolar 
Psychopathic Personality Disorder 
No other psychiatric illness 
1 
2 
1 
1 
1 
2 
1 
1 
1 
1 
6 
1 
1 
16 
Some of the major physical complica-
tions of Pentazocine misuse seen in this 
group of patients are skin ulcers (10), SHEKHAR SAXENA ET AL  151 
cellulitis (4), accidents (2) and sei-
zures (1). 
Management was attempted in the in-
patient setting for majority of patients and 
consisted of sudden withdrawal of Penta-
zocine, symptomatic treatment of withdra-
wal effects by non-opiate drugs, investiga-
tions and vigorous management for pre-
existing physical illness and supportive psy-
chotherapy. The outcome of management 
is summarized in Table 3. 
Table 3 
Outcome of Management 
Terminated treatment against medical advice 9 
Successful withdrawal but no follow-up 4 
available 
Successful withdrawal with abstinence at 5 
6 month follow-up 
Discussion 
Collection of eighteen cases of Penta-
zocine abuse from a single hospital in a 
short period indicates that this condition is 
not as rare as hitherto believed. It is possible 
that abuse of Pentazocine is not recognized 
commonly because of inadequate perception 
of this problem by medical professionals. 
The present series of cases is restricted 
only to parenteral abuse of Pentazocine. 
The amount of drug consumed by most of 
the patients was much higher than the rout-
ine therapeutic dose, indicating the deve-
lopment of tolerance. Withdrawal symp-
toms were present in all patients even when 
the possible effects of other opiate withdra-
wal were excluded. These symptoms were 
typically mild to moderate in intensity and 
consisted of sleeplessness, restlessness, irri-
tability, tremors, generalized bodyache and 
increase in any pre-existing local pain. Psy-
chological craving for the drug was intense 
in all the regular abusers. Frequently, they 
pleaded for 'one more injection' or ma-
naged to get some through a sympathetic 
relative, in the withdrawal period. 
The patients of the present series can be 
roughly divided into two categories on the 
basis of their pattern of abuse. 
I. Abuse related to chronic pain : These pa-
tients had some chronic painful physical 
illness and the beginning of Pentazocine 
use was related to relief of pain. Howev-
er, subsequently, the high dose, the fre-
quency of administration, withdrawal 
effects and the intense drug seeking be-
haviour clearly indicated that the drug 
was no more being taken for relief of 
pain only. Withdrawal from the drug 
was extremely difficult and mostly un-
successful because patients insisted that 
they were taking Pentazocine only for 
pain relief. They refused to accept the 
presence of abuse or dependence, hence 
did not co-operate in treatment. Most of 
these patients discontinued treatment 
against medical advice after a variable 
interval of time. 
II. Abuse unrelated to pain: These patients 
had abused other drugs also and they 
were administering Pentazocine only 
for its pleasurable psychological effects. 
Pentazocine was used by some patients 
as a substitute for Pethidine, when the 
latter was not available. This observa-
tion is significant as Pentazocine is 
known to be a partial antagonist of Mor-
phine and allied drugs, capable of induc-
ing withdrawal syndrome. Three pa-
tients were abusing 'Mandrax' (a combi-
nation of Methaquolone and Diphen-
hydramine) also, however, it was not be-
ing taken simultaneously with Penta-
zocine. Withdrawal from Pentazocine 
was successful in most of patients in this 
group, however abuse of other drugs 
continued. PENTAZOCINE ABUSE 
The high proportion of medical and re-
lated professions in this series is explanable 
on the basis ot knowledge and easy availa-
bility of Pentazocine to them. However, 
what is significant is that the abuse is not li-
mited to these professions and a number of 
patients from other occupations have also 
been abusing Pentazocine. Keeping in view 
the extensive use ot this drug in medical, 
surgical as well as general practice and its 
almost unrestricted availability, Pentazoc-
ine abuse may become a serious problem in 
the coming years. Hence there is need for 
more judicious use of this drug by medical 
profession as well as more strict control on its 
sale by the relevant government agencies. 
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